AVITA Medical, Inc. (RCEL) Receivables - Other (2019 - 2024)

AVITA Medical (RCEL) has reported Receivables - Other for 6 consecutive years, with -$55000.0 the latest figure, recorded in Q4 2024.

• For the quarter ending Q4 2024, Receivables - Other rose 67.84% year-over-year to -$55000.0; the trailing twelve-month figure through Dec 2024 stood at -$3.5 million (down 3623.47% YoY), and the FY2024 full-year result was $56000.0, up 106.45% from the prior year.
• Receivables - Other declined to -$55000.0 in Q4 2024 per RCEL's latest filing, from $111000.0 in the prior quarter.
• Across five years, Receivables - Other topped out at $3.5 million in Q2 2021 and bottomed at -$3.3 million in Q3 2021.
• Historically, Receivables - Other has averaged $392850.0 across 5 years, with a median of $323000.0 in 2021.
• The widest YoY moves for Receivables - Other: up 958.97% in 2021, down 998.38% in 2021.
• Over 5 years, Receivables - Other stood at $440000.0 in 2020, then decreased by 30.0% to $308000.0 in 2021, then tumbled by 65.58% to $106000.0 in 2022, then slumped by 261.32% to -$171000.0 in 2023, then jumped by 67.84% to -$55000.0 in 2024.
• According to Business Quant data, Receivables - Other over the past three periods registered -$55000.0, $111000.0, and $94000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.